{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 470631860 | IUPAC_name = N-Hydroxy-N-phenyloctanediamide | image = Vorinostat.svg | width = 275 | pronounce = | tradename = Zolinza | Drugs.com = | MedlinePlus = a607050 | licence_US = Vorinostat | pregnancy_AU = | pregnancy_US = D | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = Rx-only | legal_status = Rx-only | routes_of_administration = Oral (capsules) | bioavailability = 1.8–11% | protein_bound = ~71% | metabolism = Hepatic glucuronidation and β-oxidationCYP system not involved | metabolites = vorinostat O-glucuronide, 4-anilino-4-oxobutanoic acid (both inactive) | elimination_half-life = ~2 hours (vorinostat and O-glucuronide), 11 hours (4-anilino-4-oxobutanoic acid) | excretion = Renal (negligible) | IUPHAR_ligand = 6852 | CAS_number_Ref = | CAS_number = 149647-78-9 | ATC_prefix = L01 | ATC_suffix = XH01 | PubChem = 5311 | DrugBank_Ref = | DrugBank = DB02546 | ChemSpiderID_Ref = | ChemSpiderID = 5120 | UNII_Ref = | UNII = 58IFB293JI | KEGG_Ref = | KEGG = D06320 | ChEBI_Ref = | ChEBI = 45716 | ChEMBL_Ref = | ChEMBL = 98 | C=14 | H=20 | N=2 | O=3 | smiles = O=C(Nc1ccccc1)CCCCCCC(=O)NO | StdInChI_Ref = | StdInChI = 1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18) | StdInChIKey_Ref = | StdInChIKey = WAEXFXRVDQXREF-UHFFFAOYSA-N }}Vorinostat (rINN) also known as Suberoylanilide hydroxamic acid (suberoyl+anilide+hydroxamic acid abbreviated as SAHA) is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities. Vorinostat is marketed under the name Zolinza''' ( ) by Merck for the treatment of cutaneous manifestations in patients with cutaneous T cell lymphoma (CTCL) when the disease persists, gets worse, or comes back during or after two systemic therapies. The compound was developed by Columbia University chemist Ronald Breslow and Memorial Sloan-Kettering researcher Paul Marks Medical uses Vorinostat was the first histone deacetylase inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of CTCL on October 6, 2006. It also failed to demonstrate efficacy in treating acute myeloid leukemia in a phase II study. Development In 1966, Charlotte Friend published her observation that a suspension of murine erythroleukemia cells underwent cytodifferentiation to normal erythrocytes when treated with dimethylsulfoxide (DMSO, a common drug solvent and cryoprotectant frequently used for cell culture freezing) at 280 mmolar. Memorial Sloan-Kettering researcher Paul Marks approached Columbia University chemist Ronald Breslow about these